Image by PIRO4D on Pixabay
When the AVID-CC trial opens to recruitment, this section will display a recruitment thermometer showing our current recruitment figure versus our target!
AVID-CC will be delivered by hospital at home teams - this is a relatively new model of care in which hospital based teams reach out into the community to deliver care with the specific intent of avoiding admission to hospital.
We are hoping to enrol up to 750 men and women aged 18 or over who are in community care across the UK to take part in our AVID-CC trial.
To find out what would be involved if you chose to take part, including the potential benefits and risks, click here.
Adalimumab is an antibody drug which works against a chemical signalling molecule called Tumour Necrosis Factor. Tumour Necrosis Factor (TNF) switches on the body’s immune system to fight infections.
In some inflammatory diseases such as rheumatoid arthritis there is too much TNF and blocking it helps control the disease.
There is evidence that TNF is raised in COVID-19 so in the AVID-CC trial we are investigating whether blocking TNF is helpful in COVID-19. In this trial, Adalimumab will be given by injection under the skin (subcutaneous).
This section will provide the latest news updates from the AVID-CC trial. The trial is currently in set-up and the team hopes to open to recruitment soon!
Last updated: Weds 12th August 2020